A Phase III Study of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Poor Efficacy of MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
Phase of Trial: Phase III
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Methotrexate (Primary) ; RC 18 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors RemeGen
- 31 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 31 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2019.
- 12 Jan 2017 New trial record